Last reviewed · How we verify

Recurrent herpes simplex labialis — Treatment Landscape & Competitive Intelligence

Recurrent herpes simplex labialis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Recurrent herpes simplex labialis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Famvir FAMCICLOVIR Novartis Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 1994-01-01
Zovirax ACYCLOVIR Ligand Pharms Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] Purine nucleoside phosphorylase 1982-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Aciclovir Aciclovir Assistance Publique Hopitaux De Marseille Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
ACYC ACYC Ligand Pharms Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ligand Pharms · 2 drugs in Recurrent herpes simplex labialis
  2. · 1 drug in Recurrent herpes simplex labialis
  3. Assistance Publique Hopitaux De Marseille · 1 drug in Recurrent herpes simplex labialis
  4. Generic (originally Merck/Upjohn) · 1 drug in Recurrent herpes simplex labialis
  5. Novartis · 1 drug in Recurrent herpes simplex labialis
  6. University of Zurich · 1 drug in Recurrent herpes simplex labialis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Recurrent herpes simplex labialis:

Cite this brief

Drug Landscape (2026). Recurrent herpes simplex labialis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/recurrent-herpes-simplex-labialis. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing